← All trials
NCT06435039
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 26, 2024
- Primary completion
- Aug 21, 2024
- Completion date
- Oct 22, 2024
- First posted
- May 30, 2024
- Last posted
- May 30, 2024
- Enrollment
- 32
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Syneos HealthLead sponsor
- Jiangsu Asieris Pharmaceutical Technology Co., Ltd.Collaborator
- Jiangsu Asieris Pharmaceutical Technology Co., Ltd.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.